Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B.
Adefovir (ADV) sequential monotherapy was included in the 2005 Asia-Pacific guidelines for the management of patients with lamivudine (LAM) resistance. However, following the development of ADV resistance, the proportion of resistant variants during combined rescue therapy with ADV and entecavir (ETV) were unknown. The present study characterized the dynamics of resistant variants in patients with chronic hepatitis B (CHB) and LAM-resistant variants during antiviral therapy consisting of ADV monotherapy followed by ADV-ETV combination therapy. A total of 3 patients were selected from a cohort of 55 patients with CHB due to developing ADV resistance. The patients had been previously treated with LAM (100 mg daily) for 21-24 months. At the initiation of sequential monotherapy with ADV, LAM-resistant variants (rtM204V/I and rtL180M) were detected in the three patients. These patients developed ADV resistance during 19-30 months of ADV sequential monotherapy, and then switched their antiviral regimen to ADV-ETV combination therapy. During ADV monotherapy and ADV-ETV combination therapy, the patients were monitored every 3 months for the first year of therapy, and then every 6 months thereafter. A total of 30 serum samples were collected from the patients throughout the monitoring period. In total, 10 mutants that were associated with commonly-used antiviral drugs were detected by pyrosequencing. During ADV sequential monotherapy, LAM-resistant variants were gradually decreased, whereas ADV-resistant rtA181V/T and rtN236T variants gradually increased in the viral population. During 30-41 months of ADV-ETV combination therapy, viral load reduction was 2.59-3.28 log10copies/ml; ADV-resistant variants rtA181T/V and rtN236T were undetectable following 11-24 months of combination therapy; and rtL180M and rtM204I/V remained dominant in the viral population. In conclusion, the results of the present study suggested that, in patients with LAM and ADV-resistant variants that developed during LAM-ADV sequential monotherapy, ETV-ADV combination therapy may partially inhibit the replication of HBV DNA; however, LAM-resistant rtL180M and rtM204I/V variants remained predominant following 30-41 months combination therapy.
Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, P.R. China.
Yang
Y
Wang
Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, P.R. China.
Shuang
S
Liu
Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, P.R. China.
Y U
YU
Chen
Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, P.R. China.
Sujun
S
Zheng
Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, P.R. China.
L I
LI
Zhou
Department of Microbiology and Infectious Diseases, Peking University Health Science Center, Beijing 100083, P.R. China.
Fengmin
F
Lu
Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, P.R. China.
Zhongping
Z
Duan
adefovir; entecavir; hepatitis B virus; lamivudine resistance; multidrug resistance; rescue therapy